Christoph Westphal, M.D., Ph.D., CEO and co-founder of Sirtris Pharmaceuticals, Rings the NASDAQ Opening Bell
October 16, 2007 - Times Square, NYC
About this Marketsite Event:
Christoph Westphal, M.D., Ph.D., CEO and co-founder of Sirtris Pharmaceuticals, presides over the opening bell. He will be joined by members of the Sirtris management team including Garen Bohlin, Chief Operating Officer, Peter Elliot, Ph.D., SVP Development, Michael Jirousek, Ph.D., SVP Research, Paul Brannelly, VP Finance, Michelle Dipp, M.D., Ph.D., Director of Corporate Development, and David Sinclair, Ph.D., co-founder and member of the Board of Directors of Sirtris.
Headquartered in Cambridge, Massachusetts, Sirtris Pharmaceuticals
(Nasdaq:SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. The company's drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process.
More information about the company is available at www.sirtrispharma.com.
Press Inquiries Only:
Organizations interested in obtaining NASDAQ-listed company bell ringing ceremony photographs for press purposes, must first receive approval from the listed company before requesting photographs from NASDAQ. Please provide the company contact information from whom you received approval to Jolene Libretto at
jolene.libretto@nasdaq.com. Kindly credit © 2007, The Nasdaq Stock Market, Inc. Reprinted with permission.
Other Photography Inquiries:
For all other photography inquiries, please contact NASDAQ’s photographer, Rob Tannenbaum at
rob.tannenbaum@nasdaq.com.
© Copyright 2007, The NASDAQ Stock Market, Inc.
Reprinted with the permission of The Nasdaq Stock Market, Inc.
